Herbal Firm Denied Supreme Court Hearing Over Cancer Claim
This article was originally published in The Tan Sheet
Executive Summary
The Supreme Court will not consider herbal supplement marketer Daniel Chapter One's argument that the right to freedom of religion allows the firm to claim its products cure cancer.
You may also be interested in...
Regulatory News In Brief
FDA breaks out topical acne OTC guidance
In Brief
Colgate Buys Sanex Deodorants
FTC affirms cancer cures case ruling
Daniel Chapter One must notify customers it made deceptive and unsubstantiated cancer cure claims for its herbal products after failing in its appeal of an administrative law judge's ruling to uphold Federal Trade Commission charges. The commission's unanimous 1opinion, announced Dec. 24, says respondents Daniel Chapter One and James Feijo "lacked a reasonable basis to substantiate" claims their products BioShark, 7 Herb Formula and others inhibit tumor growth and are effective cancer treatments. Like other companies charged in FTC's 2008 enforcement sweep against bogus cancer cure claims, Providence, R.I.-based Daniel Chapter One is enjoined from making such claims without supporting scientific evidence (2"The Tan Sheet" Aug. 17, 2009, In Brief)